Quarterly report pursuant to Section 13 or 15(d)

Stockholders Equity (Details)

Stockholders Equity (Details) - USD ($)
$ / shares in Units, $ in Thousands
1 Months Ended 3 Months Ended
Mar. 29, 2022
Dec. 31, 2021
Oct. 31, 2021
Dec. 31, 2020
Mar. 31, 2022
Nov. 30, 2017
Stockholders Equity (Details) [Line Items]            
Market sales agreement, description       pursuant to a registration statement on Form S-3 declared effective by the Securities and Exchange Commission on December 11, 2020, the Company entered into an Open Market Sales Agreement (“ATM Agreement”) with Jefferies LLC. (“Jefferies”), which provides that, upon the terms and subject to the conditions and limitations in the ATM Agreement, the Company may elect, from time to time, to offer and sell shares of Common Stock with an aggregate offering price of up to $50,000, with Jefferies acting as sales agent. During the three months ended March 31, 2022, the Company sold 27,171 shares of Common Stock under the ATM Agreement, at an average price of $1.36 per share, raising aggregate net proceeds of approximately $37, after deducting an aggregate commission of $1.    
Preferred stock, shares authorized   1,000,000     1,000,000  
Preferred stock, par value   $ 0.0001     $ 0.0001  
Fair value at the grant date         $ 1,307  
Shares of issued warrants           2,974
Warrants, description         The warrants were fully vested at their grant date and will expire immediately prior to a consummation of an M&A transaction.  
Stock Options [Member]            
Stockholders Equity (Details) [Line Items]            
Grant options $ 1,153,500          
Exercise price $ 1.41          
Vesting period 4 years          
Maruho Agreement [Member]            
Stockholders Equity (Details) [Line Items]            
Common stock shares issued     375,000      
Common stock per share     $ 8      
Total gross proceed     $ 3,000      
Grant date fair value     1,024      
Contract liability     $ 1,976      
CFF Agreement [Member]            
Stockholders Equity (Details) [Line Items]            
Agreement type, description   the Company entered into a Securities Purchase Agreement with the Cystic Fibrosis Foundation (“CF Foundation”), an organization that historically played a role in supporting the development of innovative therapies for patients suffering from cystic fibrosis (CF). Under the terms of the agreement, the Company will receive up to $5,000 in two tranches. In the first tranche, which closed and fully received on December 21, 2021, the CF Foundation invested $3,000 as an initial equity investment based on a share price of $2.57. Upon completion of patient dosing in Part 1 of the Company’s Phase 1b/2a study of BX004, the Company would have the right to receive the second tranche of $2,000, also as an equity investment. In the event that the average closing price of the Common Stock for the ten trading days prior to the second tranche completion is less than $2.57, the Company shall have the right in its sole discretion to waive the second tranche payment and in such event the CF Foundation shall not have any right to receive additional shares. The Company concluded that the second tranche is a freestanding financial instrument.